Department of Urology, University of Illinois at Chicago, Chicago, Illinois.
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
J Urol. 2018 Nov;200(5):1062-1067. doi: 10.1016/j.juro.2018.06.018. Epub 2018 Jun 12.
Prostate biopsy complications have important consequences that may affect patient compliance with rebiopsy schemes. However, to our knowledge this has not been studied in earnest. Thus, we evaluated whether previous prostate biopsy related complications and the type of complication were associated with repeat prostate biopsy compliance in a clinical trial with study mandated systematic biopsies.
We retrospectively analyzed the records of 4,939 men 50 to 75 years old who underwent 2-year prostate biopsy and were recommended to undergo 4-year prostate rebiopsy in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) study. The analyzed biopsy complications were hematuria, urinary tract infection, acute urinary retention and hemospermia.
A total of 260 men (5.3%) had a 2-year prostate biopsy related complication, including hematuria in 180 (3.6%), urinary tract infection in 36 (0.7%), acute urinary retention in 26 (0.5%) and hemospermia in 102 (2.1%). A total of 474 men (9.6%) were noncompliant with 4-year rebiopsy. On univariable analysis any previous complication (OR 1.56, 95% CI 1.08-2.24, p = 0.018), urinary tract infection (OR 2.72, 95% CI 1.23-6.00, p = 0.013), acute urinary retention (OR 4.24, 95% CI 1.83-9.81, p = 0.016) and hemospermia (OR 1.78, 95% CI 1.03-3.06, p = 0.037) were associated with rebiopsy noncompliance. Hematuria was not associated with rebiopsy noncompliance (OR 1.19, 95% CI 0.74-1.91, p = 0.483). Results were unchanged on multivariable analysis, including for any complication (OR 1.65, 95% CI 1.08-2.26, p = 0.018), for urinary tract infection (OR 2.62, 95% CI 1.07-3.21, p = 0.029), for acute urinary retention (OR 4.51, 95% CI 1.93-10.54, p = 0.001), for hemospermia (OR 1.85, 95% CI 1.07-3.21, p = 0.029) and for hematuria (OR 1.19, 95% CI 0.74-1.93, p = 0.472).
In men who undergo repeat prostate biopsy a previous biopsy related complication and the type of complication were associated with lower compliance with rebiopsy schemes. Patients who experience biopsy related complications are ideal candidates to receive intervention regarding the importance of prostate rebiopsy to prevent noncompliance.
前列腺活检的并发症会产生重要后果,可能会影响患者对再次活检方案的依从性。然而,据我们所知,这方面尚未得到认真研究。因此,我们评估了在一项有研究规定的系统活检的临床试验中,先前的前列腺活检相关并发症及其类型是否与重复前列腺活检的依从性有关。
我们回顾性分析了 4939 名 50 至 75 岁的男性的记录,他们在 REDUCE(多沙唑嗪减少前列腺癌事件)研究中接受了 2 年的前列腺活检,并被建议进行 4 年的前列腺再活检。分析的活检并发症包括血尿、尿路感染、急性尿潴留和血精。
共有 260 名男性(5.3%)出现了 2 年的前列腺活检相关并发症,包括血尿 180 名(3.6%)、尿路感染 36 名(0.7%)、急性尿潴留 26 名(0.5%)和血精 102 名(2.1%)。共有 474 名男性(9.6%)未进行 4 年的再活检。单变量分析显示,任何先前的并发症(OR 1.56,95%CI 1.08-2.24,p=0.018)、尿路感染(OR 2.72,95%CI 1.23-6.00,p=0.013)、急性尿潴留(OR 4.24,95%CI 1.83-9.81,p=0.016)和血精(OR 1.78,95%CI 1.03-3.06,p=0.037)与再活检不依从有关。血尿与再活检不依从无关(OR 1.19,95%CI 0.74-1.91,p=0.483)。多变量分析结果不变,包括任何并发症(OR 1.65,95%CI 1.08-2.26,p=0.018)、尿路感染(OR 2.62,95%CI 1.07-3.21,p=0.029)、急性尿潴留(OR 4.51,95%CI 1.93-10.54,p=0.001)、血精(OR 1.85,95%CI 1.07-3.21,p=0.029)和血尿(OR 1.19,95%CI 0.74-1.93,p=0.472)。
在接受重复前列腺活检的男性中,先前的活检相关并发症及其类型与再活检方案的依从性较低有关。出现活检相关并发症的患者是接受关于前列腺再活检重要性的干预以预防不依从的理想人选。